Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
Four patients with Philadelphia chromosome positive CML were treated with 18-42 x 10(6) IU of purified natural leukocyte IFN-alpha per week, after high-dose chemotherapy for blast phase and attainment of 2nd chronic phase. The second blast phase occurred within 3 months in 3 patients, but one patient is still in second chronic phase after 22 months of treatment. Treatment consisted of interferon only during the first year, and interferon in combination with hydroxyurea during the second year. During the second year suppression of the Philadelphia chromosome was seen in one patient, with 20% Philadelphia negative bone marrow metaphases. The toxicity of purified natural leukocyte IFN-alpha was similar to the toxicity of recombinant IFN-alpha. Antibodies to IFN-alpha were not detected in any patient.
Wahlin
A
A
Department of Medicine, University Hospital, Umeå, Sweden.
Holm
J
J
Engman
K
K
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use* / Q000633:toxicity; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000473:pathology / Q000628:therapy*; D007958:Leukocyte Count / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects
D006454:Hemoglobins; D007370:Interferon Type I; D006918:Hydroxyurea